ziprasidone Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
2865 146939-27-7

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • ziprasidone
  • zaprasidone
  • ziprasidone hydrochloride
  • ziprasidone mesylate
  • geodon
  • ziprasidone HCl
  • ziprasidone mesilate
a benzisothiazoylpiperazine derivative; has combined dopamine and serotonin receptor antagonist activity; structurally related to tiospirone
  • Molecular weight: 412.94
  • Formula: C21H21ClN4OS
  • CLOGP: 4.21
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 1
  • TPSA: 48.47
  • ALOGS: -4.76
  • ROTB: 4

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
80 mg O
40 mg P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.00 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0.50 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 6.36 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 60 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 1 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 5.10 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.00 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 3.10 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Feb. 5, 2001 FDA PFIZER

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Tardive dyskinesia 721.26 17.43 214 16858 7329 46661661
Dystonia 692.87 17.43 228 16844 11029 46657961
Blood prolactin abnormal 501.55 17.43 112 16960 1177 46667813
Sedation 495.58 17.43 216 16856 22694 46646296
Sexual dysfunction 481.17 17.43 122 16950 2281 46666709
Anosognosia 417.38 17.43 98 16974 1307 46667683
Disturbance in social behaviour 381.96 17.43 95 16977 1636 46667354
Dyskinesia 364.52 17.43 188 16884 28737 46640253
Extrapyramidal disorder 358.26 17.43 140 16932 11128 46657862
Neuroleptic malignant syndrome 331.89 17.43 132 16940 10990 46658000
Metabolic disorder 314.14 17.43 100 16972 4332 46664658
Akathisia 277.91 17.43 105 16967 7609 46661381
Personality change 273.79 17.43 94 16978 5164 46663826
Suicide attempt 250.79 17.43 187 16885 54849 46614141
Completed suicide 227.43 17.43 273 16799 145647 46523343
Electrocardiogram QT prolonged 187.33 17.43 153 16919 51172 46617818
Parkinsonism 168.60 17.43 74 16998 7874 46661116
Schizophrenia 160.11 17.43 73 16999 8495 46660495
Psychotic disorder 152.77 17.43 98 16974 22523 46646467
Orthostatic hypertension 149.00 17.43 30 17042 181 46668809
Suicidal ideation 134.06 17.43 132 16940 56250 46612740
Mania 132.18 17.43 69 17003 10777 46658213
Agitation 117.58 17.43 122 16950 55293 46613697
Tremor 116.36 17.43 175 16897 115464 46553526
Blood prolactin increased 115.52 17.43 43 17029 2984 46666006
Metabolic syndrome 112.10 17.43 34 17038 1250 46667740
Diabetes mellitus 109.42 17.43 112 16960 49953 46619037
Weight increased 101.04 17.43 200 16872 164273 46504717
Blood glucose increased 99.45 17.43 127 16945 71886 46597104
Hallucination, auditory 99.41 17.43 57 17015 10699 46658291
Galactorrhoea 89.18 17.43 38 17034 3759 46665231
Paranoia 84.38 17.43 51 17021 10546 46658444
Oculogyric crisis 83.97 17.43 27 17045 1206 46667784
Type 2 diabetes mellitus 82.59 17.43 64 17008 19811 46649179
Anxiety 76.35 17.43 190 16882 181767 46487223
Obesity 70.75 17.43 51 17021 14155 46654835
Insurance issue 70.57 17.43 26 17046 1752 46667238
Torsade de pointes 66.00 17.43 46 17026 12108 46656882
Hyperprolactinaemia 64.44 17.43 28 17044 2904 46666086
Depression 60.45 17.43 167 16905 169937 46499053
Somnolence 58.95 17.43 157 16915 156364 46512626
Respiratory arrest 56.98 17.43 66 17006 33750 46635240
Rapid eye movement sleep behaviour disorder 56.91 17.43 13 17059 152 46668838
Arthralgia 55.96 17.43 32 17040 364571 46304419
Bipolar disorder 55.74 17.43 34 17038 7143 46661847
Rheumatoid arthritis 54.16 17.43 11 17061 240204 46428786
Pneumonia 53.64 17.43 36 17036 376284 46292706
Delusion 53.06 17.43 39 17033 11149 46657841
Mental disorder 50.46 17.43 51 17021 22374 46646616
Cardio-respiratory arrest 49.62 17.43 83 16989 59786 46609204
Abnormal behaviour 49.43 17.43 49 17023 21009 46647981
Catatonia 48.89 17.43 25 17047 3737 46665253
Insomnia 48.14 17.43 151 16921 164773 46504217
Psychomotor hyperactivity 44.44 17.43 33 17039 9580 46659410
Restlessness 43.30 17.43 50 17022 25474 46643516
Diarrhoea 42.77 17.43 88 16984 559514 46109476
Aggression 42.76 17.43 47 17025 22697 46646293
Muscle rigidity 41.20 17.43 32 17040 9929 46659061
Peripheral swelling 40.65 17.43 5 17067 158066 46510924
Overdose 39.06 17.43 103 16969 101876 46567114
Pain 39.02 17.43 72 17000 476876 46192114
Posture abnormal 38.83 17.43 18 17054 2172 46666818
Blood triglycerides increased 38.52 17.43 33 17039 11750 46657240
Impulse-control disorder 38.25 17.43 13 17059 691 46668299
Reduced facial expression 38.18 17.43 15 17057 1205 46667785
Cardiac arrest 31.31 17.43 88 16984 90311 46578679
Hallucination 30.88 17.43 61 17011 49890 46619100
Irritability 30.75 17.43 45 17027 28901 46640089
Tachyphrenia 30.55 17.43 13 17059 1281 46667709
Swollen tongue 30.41 17.43 45 17027 29187 46639803
Rabbit syndrome 30.12 17.43 9 17063 314 46668676
Cardiac hypertrophy 29.62 17.43 12 17060 1045 46667945
Pyrexia 29.06 17.43 52 17020 348750 46320240
Muscle twitching 28.76 17.43 31 17041 14641 46654349
Thrombocytopenia 28.08 17.43 6 17066 126575 46542415
Mental status changes 27.87 17.43 50 17022 38038 46630952
Dyslipidaemia 27.83 17.43 20 17052 5520 46663470
Thinking abnormal 27.13 17.43 25 17047 9789 46659201
Drooling 26.98 17.43 16 17056 3193 46665797
Haemoglobin decreased 26.85 17.43 7 17065 128942 46540048
Drug withdrawal syndrome 26.84 17.43 41 17031 27343 46641647
Torticollis 26.67 17.43 13 17059 1754 46667236
Seizure 26.57 17.43 102 16970 122952 46546038
Schizoaffective disorder 25.95 17.43 12 17060 1440 46667550
Trismus 25.64 17.43 16 17056 3499 46665491
Breast enlargement 25.60 17.43 12 17060 1485 46667505
Echolalia 25.54 17.43 7 17065 178 46668812
Sepsis 25.40 17.43 9 17063 136005 46532985
Bruxism 25.26 17.43 15 17057 3002 46665988
Condition aggravated 24.90 17.43 164 16908 244888 46424102
Decreased eye contact 24.76 17.43 6 17066 92 46668898
Product substitution issue 24.75 17.43 29 17043 15002 46653988
Cough 24.38 17.43 29 17043 230220 46438770
Anaemia 24.23 17.43 35 17037 255744 46413246
Withdrawal syndrome 23.46 17.43 31 17041 18103 46650887
Joint swelling 23.45 17.43 16 17056 166057 46502933
Substance abuse 23.15 17.43 16 17056 4151 46664839
Pain in extremity 22.96 17.43 37 17035 258643 46410347
General physical health deterioration 22.77 17.43 7 17065 115762 46553228
Suicidal behaviour 22.68 17.43 13 17059 2435 46666555
Cogwheel rigidity 22.60 17.43 11 17061 1479 46667511
Toxicity to various agents 22.28 17.43 143 16929 211623 46457367
Dysphoria 21.76 17.43 16 17056 4573 46664417
Apathy 21.04 17.43 19 17053 7249 46661741
Arthropathy 20.99 17.43 3 17069 84697 46584293
Dysphagia 20.89 17.43 69 17003 77243 46591747
Nausea 20.74 17.43 157 16915 687297 45981693
Drug hypersensitivity 20.56 17.43 156 16916 243669 46425321
Hostility 20.50 17.43 10 17062 1352 46667638
Nasopharyngitis 20.23 17.43 16 17056 153982 46515008
Injection site pain 20.16 17.43 7 17065 107145 46561845
Organ failure 19.77 17.43 12 17060 2498 46666492
Acute kidney injury 19.76 17.43 35 17037 235820 46433170
Stereotypy 19.75 17.43 7 17065 422 46668568
Treatment failure 19.47 17.43 5 17067 93082 46575908
Drug screen positive 19.44 17.43 14 17058 3877 46665113
Cardiac failure 19.43 17.43 3 17069 79945 46589045
Intentional overdose 19.40 17.43 60 17012 64884 46604106
Grimacing 19.31 17.43 7 17065 450 46668540
Coprolalia 19.11 17.43 4 17068 30 46668960
Diabetic coma 18.98 17.43 8 17064 770 46668220
Rhabdomyolysis 18.82 17.43 45 17027 41864 46627126
Lactation disorder 18.81 17.43 6 17066 261 46668729
Infection 18.68 17.43 13 17059 133579 46535411
Exposure via ingestion 18.53 17.43 13 17059 3454 46665536
Blood creatine phosphokinase increased 18.52 17.43 35 17037 27689 46641301
Abdominal pain 18.50 17.43 35 17037 229996 46438994
Tic 18.38 17.43 9 17063 1227 46667763
Obsessive thoughts 18.29 17.43 7 17065 524 46668466
Anger 18.08 17.43 22 17050 11830 46657160
Homicidal ideation 17.86 17.43 10 17062 1792 46667198
Female sexual dysfunction 17.82 17.43 4 17068 43 46668947
Amenorrhoea 17.79 17.43 19 17053 8876 46660114
Granulocytopenia 17.71 17.43 15 17057 5258 46663732
Pressure of speech 17.69 17.43 7 17065 573 46668417
Sinusitis 17.66 17.43 13 17059 129755 46539235
Pituitary hyperplasia 17.45 17.43 3 17069 6 46668984

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Dystonia 408.30 19.75 151 11666 9576 29931085
Neuroleptic malignant syndrome 298.51 19.75 140 11677 16155 29924506
Tardive dyskinesia 266.64 19.75 93 11724 4964 29935697
Dyskinesia 243.04 19.75 134 11683 21700 29918961
Sedation 223.09 19.75 115 11702 16258 29924403
Anosognosia 215.97 19.75 51 11766 643 29940018
Akathisia 201.97 19.75 79 11738 5825 29934836
Blood prolactin abnormal 197.24 19.75 48 11769 693 29939968
Extrapyramidal disorder 193.03 19.75 91 11726 10602 29930059
Disturbance in social behaviour 173.49 19.75 50 11767 1421 29939240
Weight increased 150.82 19.75 166 11651 74747 29865914
Psychotic disorder 145.68 19.75 96 11721 21419 29919242
Agitation 139.68 19.75 137 11680 53936 29886725
Aggression 135.58 19.75 114 11703 36793 29903868
Sexual dysfunction 133.23 19.75 59 11758 5942 29934719
Euphoric mood 124.48 19.75 51 11766 4239 29936422
Priapism 122.86 19.75 52 11765 4691 29935970
Metabolic disorder 122.35 19.75 48 11769 3563 29937098
Obsessive-compulsive disorder 115.98 19.75 48 11769 4093 29936568
Antipsychotic drug level below therapeutic 115.70 19.75 36 11781 1336 29939325
Suicide attempt 113.91 19.75 103 11714 36594 29904067
Homicidal ideation 113.47 19.75 41 11776 2422 29938239
Schizophrenia 110.20 19.75 59 11758 8989 29931672
Electrocardiogram QT prolonged 108.12 19.75 99 11718 35736 29904925
Disinhibition 107.00 19.75 37 11780 1920 29938741
Therapeutic product effect variable 106.94 19.75 34 11783 1355 29939306
Suicidal ideation 103.60 19.75 97 11720 36017 29904644
Bruxism 99.43 19.75 32 11785 1327 29939334
Oppositional defiant disorder 96.65 19.75 24 11793 378 29940283
Completed suicide 94.95 19.75 153 11664 99339 29841322
Decreased eye contact 89.85 19.75 23 11794 412 29940249
Personality change 88.70 19.75 41 11776 4559 29936102
Obesity 88.25 19.75 50 11767 8505 29932156
Mania 82.48 19.75 49 11768 9105 29931556
Increased appetite 78.00 19.75 40 11777 5577 29935084
Paranoia 77.64 19.75 49 11768 10139 29930522
Hallucination, auditory 74.39 19.75 47 11770 9742 29930919
Anxiety 72.14 19.75 128 11689 89743 29850918
Trismus 71.63 19.75 29 11788 2336 29938325
Oculogyric crisis 71.33 19.75 25 11792 1350 29939311
Swollen tongue 63.92 19.75 48 11769 13144 29927517
Catatonia 63.17 19.75 32 11785 4348 29936313
Serotonin syndrome 63.03 19.75 54 11763 17837 29922824
Delusion 58.93 19.75 44 11773 11945 29928716
Psychomotor hyperactivity 56.35 19.75 37 11780 8187 29932474
Crying 55.74 19.75 32 11785 5577 29935084
Drug ineffective 55.08 19.75 272 11545 340115 29600546
Tic 55.02 19.75 23 11794 2009 29938652
Choreoathetosis 52.21 19.75 18 11799 925 29939736
Irritability 51.37 19.75 54 11763 22996 29917665
Bipolar disorder 49.86 19.75 26 11791 3750 29936911
Somnolence 49.14 19.75 114 11703 96649 29844012
Parkinsonism 48.09 19.75 32 11785 7237 29933424
Diarrhoea 46.92 19.75 38 11779 334065 29606596
Speech disorder 46.91 19.75 53 11764 24459 29916202
Pneumonia 45.74 19.75 39 11778 334267 29606394
Coordination abnormal 45.56 19.75 31 11786 7274 29933387
Blood prolactin increased 45.01 19.75 18 11799 1404 29939257
Anaemia 43.50 19.75 14 11803 207978 29732683
Tremor 42.96 19.75 93 11724 75270 29865391
Affect lability 40.79 19.75 22 11795 3396 29937265
Diabetes mellitus 40.67 19.75 65 11752 41800 29898861
Muscle rigidity 40.33 19.75 33 11784 10228 29930433
Insomnia 38.93 19.75 102 11715 93234 29847427
Abnormal behaviour 38.52 19.75 49 11768 25574 29915087
Dyslipidaemia 37.38 19.75 25 11792 5702 29934959
Blood glucose increased 36.28 19.75 77 11740 61453 29879208
Type 2 diabetes mellitus 35.99 19.75 35 11782 13587 29927074
Schizoaffective disorder 35.58 19.75 14 11803 1046 29939615
Granulocytopenia 35.48 19.75 25 11792 6201 29934460
Acute kidney injury 34.96 19.75 34 11783 273808 29666853
Blunted affect 34.89 19.75 10 11807 278 29940383
Mood altered 33.40 19.75 27 11790 8223 29932438
Blood creatine phosphokinase increased 32.00 19.75 60 11757 43788 29896873
Torticollis 31.93 19.75 13 11804 1062 29939599
Thinking abnormal 31.84 19.75 22 11795 5289 29935372
Blood triglycerides increased 31.51 19.75 33 11784 13984 29926677
Anger 30.18 19.75 29 11788 11091 29929570
Hallucination 29.61 19.75 62 11755 48997 29891664
Grandiosity 28.92 19.75 9 11808 334 29940327
Prescribed overdose 28.44 19.75 25 11792 8536 29932125
Myopathy toxic 27.04 19.75 9 11808 415 29940246
Pyrexia 26.85 19.75 47 11770 294442 29646219
Nervousness 25.16 19.75 27 11790 11761 29928900
Depressed mood 24.69 19.75 32 11785 16997 29923664
Pruritus 24.60 19.75 8 11809 118196 29822465
Leukopenia 24.02 19.75 62 11755 56097 29884564
Abnormal palmar/plantar creases 23.76 19.75 7 11810 215 29940446
Sleep disorder 23.75 19.75 38 11779 24441 29916220
Hyperkinesia 23.64 19.75 13 11804 2085 29938576
Cough 23.63 19.75 10 11807 125632 29815029
Thrombocytopenia 22.61 19.75 13 11804 137031 29803630
Mental disorder 22.26 19.75 27 11790 13422 29927239
Tachyphrenia 22.20 19.75 10 11807 1046 29939615
Depression 22.01 19.75 82 11735 90355 29850306
Therapeutic product effect incomplete 21.87 19.75 44 11773 33790 29906871
Drooling 21.76 19.75 14 11803 2991 29937670
Renal failure 21.61 19.75 12 11805 128954 29811707
Haemoglobin decreased 21.58 19.75 9 11808 114089 29826572
Disease progression 21.49 19.75 3 11814 79871 29860790
Death 21.48 19.75 71 11746 357212 29583449
Condition aggravated 21.29 19.75 109 11708 137757 29802904
Gynaecomastia 21.20 19.75 21 11796 8330 29932331
Pharyngeal dystonia 20.52 19.75 3 11814 0 29940661
Restlessness 20.45 19.75 34 11783 22565 29918096
Asthenia 20.43 19.75 35 11782 221255 29719406
Streptococcal infection 20.32 19.75 16 11801 4692 29935969

Pharmacologic Action:

SourceCodeDescription
ATC N05AE04 NERVOUS SYSTEM
PSYCHOLEPTICS
ANTIPSYCHOTICS
Indole derivatives
FDA EPC N0000175430 Atypical Antipsychotic
MeSH PA D014150 Antipsychotic Agents
MeSH PA D002491 Central Nervous System Agents
MeSH PA D002492 Central Nervous System Depressants
MeSH PA D015259 Dopamine Agents
MeSH PA D018492 Dopamine Antagonists
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D011619 Psychotropic Drugs
MeSH PA D018490 Serotonin Agents
MeSH PA D012702 Serotonin Antagonists
MeSH PA D014149 Tranquilizing Agents
CHEBI has role CHEBI:35471 psychopharmaceuticals
CHEBI has role CHEBI:35476 grosser tranquilizer
CHEBI has role CHEBI:37956 histamine receptor blocker
CHEBI has role CHEBI:48279 serotonin antagonists
CHEBI has role CHEBI:48561 dopamine blocker
CHEBI has role CHEBI:48876 antimuskarinika

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Mixed bipolar I disorder indication 16506000 DOID:3312
Schizophrenia indication 58214004 DOID:5419
Bipolar disorder in remission indication 85248005
Bipolar affective disorder, current episode manic indication 191618007
Agitation associated with Schizophrenia indication
Bipolar affective disorder, current episode depression off-label use 191627008 DOID:3312
Depression Treatment Adjunct off-label use
Tachyarrhythmia contraindication 6285003
Suicidal thoughts contraindication 6471006
Neuroleptic malignant syndrome contraindication 15244003 DOID:14464
Senile dementia contraindication 15662003
Agranulocytosis contraindication 17182001 DOID:12987
Myocardial infarction contraindication 22298006 DOID:5844
Hypovolemia contraindication 28560003
Orthostatic hypotension contraindication 28651003
Torsades de pointes contraindication 31722008
Dehydration contraindication 34095006
Dysphagia contraindication 40739000
Hypokalemia contraindication 43339004
Conduction disorder of the heart contraindication 44808001
Bradycardia contraindication 48867003
Hyperlipidemia contraindication 55822004 DOID:1168
Hepatic failure contraindication 59927004
Cerebrovascular disease contraindication 62914000 DOID:6713
Diabetes mellitus contraindication 73211009 DOID:9351
Extrapyramidal disease contraindication 76349003
Hyperglycemia contraindication 80394007 DOID:4195
Heart failure contraindication 84114007 DOID:6000
Epilepsy contraindication 84757009 DOID:1826
Leukopenia contraindication 84828003 DOID:615
Kidney disease contraindication 90708001 DOID:557
Tardive dyskinesia contraindication 102449007
Prolonged QT interval contraindication 111975006
Hypomagnesemia contraindication 190855004
Decompensated cardiac failure contraindication 195111005
Metabolic syndrome X contraindication 237602007 DOID:14221
Neutropenic disorder contraindication 303011007 DOID:1227
Severe diarrhea contraindication 409587002
Breastfeeding (mother) contraindication 413712001
Myocardial ischemia contraindication 414795007 DOID:3393
Obesity contraindication 414916001 DOID:9970
Acquired torsion dystonia contraindication 433493000
Congenital long QT syndrome contraindication 442917000
Carcinoma of female breast contraindication 447782002

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 11.26 acidic
pKa2 7.35 Basic
pKa3 0.27 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
5-hydroxytryptamine receptor 2A GPCR ANTAGONIST Ki 9.40 WOMBAT-PK CHEMBL
D(2) dopamine receptor GPCR ANTAGONIST Ki 8.32 WOMBAT-PK CHEMBL
Beta-1 adrenergic receptor GPCR Ki 5.59 PDSP
5-hydroxytryptamine receptor 5A GPCR Ki 6.54 PDSP
5-hydroxytryptamine receptor 2B GPCR Ki 7.56 PDSP
Alpha-1B adrenergic receptor GPCR Ki 8.05 PDSP
Histamine H2 receptor GPCR Ki 5.46 PDSP
D(1B) dopamine receptor GPCR Ki 6.82 PDSP
Muscarinic acetylcholine receptor M3 GPCR Ki 5 PDSP
Alpha-2C adrenergic receptor GPCR Ki 7.11 PDSP
Alpha-2B adrenergic receptor GPCR Ki 7.32 PDSP
5-hydroxytryptamine receptor 1B GPCR AGONIST Ki 8.30 IUPHAR
5-hydroxytryptamine receptor 2C GPCR ANTAGONIST Ki 8.89 WOMBAT-PK
5-hydroxytryptamine receptor 1E GPCR Ki 6.44 WOMBAT-PK
5-hydroxytryptamine receptor 3A Ion channel Ki 6.40 WOMBAT-PK
5-hydroxytryptamine receptor 1D GPCR Ki 8.70 WOMBAT-PK
Muscarinic acetylcholine receptor M1 GPCR Ki 6.55 WOMBAT-PK
Histamine H1 receptor GPCR Ki 7.33 WOMBAT-PK
Alpha-1A adrenergic receptor GPCR Ki 8 WOMBAT-PK
5-hydroxytryptamine receptor 7 GPCR Ki 8.30 WOMBAT-PK
5-hydroxytryptamine receptor 6 GPCR Ki 7.22 WOMBAT-PK
5-hydroxytryptamine receptor 1A GPCR EC50 8.47 WOMBAT-PK
Sodium-dependent serotonin transporter Transporter IC50 7 WOMBAT-PK
Potassium voltage-gated channel subfamily H member 2 Ion channel IC50 6.92 WOMBAT-PK
Alpha-2A adrenergic receptor GPCR Ki 6.30 WOMBAT-PK
Sodium-dependent noradrenaline transporter Transporter Ki 7.36 PDSP
Muscarinic acetylcholine receptor M5 GPCR Ki 5.80 PDSP
Muscarinic acetylcholine receptor M4 GPCR Ki 5.80 PDSP
Muscarinic acetylcholine receptor M2 GPCR Ki 5.52 PDSP
Beta-2 adrenergic receptor GPCR Ki 5.30 PDSP
D(1A) dopamine receptor GPCR Ki 8.02 CHEMBL
Sodium-dependent dopamine transporter Transporter WOMBAT-PK
D(4) dopamine receptor GPCR ANTAGONIST Ki 7.30 WOMBAT-PK
D(3) dopamine receptor GPCR ANTAGONIST Ki 8.14 WOMBAT-PK
Transporter Transporter Ki 7.32 CHEMBL
Histamine H1 receptor GPCR IC50 6.82 CHEMBL
Adrenergic receptor alpha-1 GPCR Ki 7.96 CHEMBL
Alpha-1A adrenergic receptor GPCR Ki 9.30 CHEMBL
D(2) dopamine receptor GPCR Ki 8.32 CHEMBL
5-hydroxytryptamine receptor 2A GPCR Ki 9.38 CHEMBL
Histamine H1 receptor GPCR Ki 7.80 CHEMBL

External reference:

IDSource
4021249 VUID
N0000148690 NUI
D02100 KEGG_DRUG
138982-67-9 SECONDARY_CAS_RN
4021249 VANDF
4030214 VANDF
4030215 VANDF
C0939698 UMLSCUI
CHEBI:32314 CHEBI
CHEMBL708 ChEMBL_ID
CHEMBL1375743 ChEMBL_ID
CHEMBL3989833 ChEMBL_ID
CHEMBL1712 ChEMBL_ID
CHEMBL1200997 ChEMBL_ID
C092292 MESH_SUPPLEMENTAL_RECORD_UI
7155 INN_ID
6UKA5VEJ6X UNII
60853 PUBCHEM_CID
59 IUPHAR_LIGAND_ID
DB00246 DRUGBANK_ID
115698 RXNORM
16791 MMSL
187736 MMSL
331404 MMSL
41113 MMSL
d04747 MMSL
009104 NDDF
009105 NDDF
009579 NDDF
129479007 SNOMEDCT_US
373389002 SNOMEDCT_US
409356003 SNOMEDCT_US
409357007 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Geodon HUMAN PRESCRIPTION DRUG LABEL 1 0049-0052 CAPSULE 20 mg ORAL NDA 32 sections
Geodon HUMAN PRESCRIPTION DRUG LABEL 1 0049-0054 CAPSULE 40 mg ORAL NDA 32 sections
Geodon HUMAN PRESCRIPTION DRUG LABEL 1 0049-0056 CAPSULE 60 mg ORAL NDA 32 sections
Geodon HUMAN PRESCRIPTION DRUG LABEL 1 0049-0058 CAPSULE 80 mg ORAL NDA 32 sections
Geodon HUMAN PRESCRIPTION DRUG LABEL 1 0049-0352 CAPSULE 20 mg ORAL NDA 32 sections
Geodon HUMAN PRESCRIPTION DRUG LABEL 1 0049-0354 CAPSULE 40 mg ORAL NDA 32 sections
Geodon HUMAN PRESCRIPTION DRUG LABEL 1 0049-0356 CAPSULE 60 mg ORAL NDA 32 sections
Geodon HUMAN PRESCRIPTION DRUG LABEL 1 0049-0358 CAPSULE 80 mg ORAL NDA 32 sections
Geodon HUMAN PRESCRIPTION DRUG LABEL 1 0049-1203 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 20 mg INTRAMUSCULAR NDA 30 sections
Geodon HUMAN PRESCRIPTION DRUG LABEL 1 0049-3920 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 20 mg INTRAMUSCULAR NDA 32 sections
Geodon HUMAN PRESCRIPTION DRUG LABEL 1 0049-3960 CAPSULE 20 mg ORAL NDA 32 sections
Geodon HUMAN PRESCRIPTION DRUG LABEL 1 0049-3980 CAPSULE 60 mg ORAL NDA 32 sections
Geodon HUMAN PRESCRIPTION DRUG LABEL 1 0049-3990 CAPSULE 80 mg ORAL NDA 32 sections
ziprasidone hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0615-7703 CAPSULE 80 mg ORAL ANDA 31 sections
ziprasidone hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0781-2164 CAPSULE 20 mg ORAL ANDA 29 sections
ziprasidone hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0781-2166 CAPSULE 40 mg ORAL ANDA 29 sections
ziprasidone hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0781-2167 CAPSULE 60 mg ORAL ANDA 29 sections
ziprasidone hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0781-2168 CAPSULE 80 mg ORAL ANDA 29 sections
Ziprasidone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0904-6269 CAPSULE 20 mg ORAL ANDA 30 sections
Ziprasidone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0904-6270 CAPSULE 40 mg ORAL ANDA 30 sections
Ziprasidone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0904-6271 CAPSULE 60 mg ORAL ANDA 30 sections
Ziprasidone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0904-6272 CAPSULE 80 mg ORAL ANDA 30 sections
GEODON HUMAN PRESCRIPTION DRUG LABEL 1 16590-895 CAPSULE 20 mg ORAL NDA 34 sections
ziprasidone hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 16714-835 CAPSULE 20 mg ORAL ANDA 30 sections
ziprasidone hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 16714-836 CAPSULE 40 mg ORAL ANDA 30 sections
ziprasidone hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 16714-837 CAPSULE 60 mg ORAL ANDA 30 sections
ziprasidone hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 16714-838 CAPSULE 80 mg ORAL ANDA 30 sections
Geodon HUMAN PRESCRIPTION DRUG LABEL 1 21695-060 CAPSULE 20 mg ORAL NDA 34 sections
Geodon HUMAN PRESCRIPTION DRUG LABEL 1 21695-061 CAPSULE 40 mg ORAL NDA 34 sections
Geodon HUMAN PRESCRIPTION DRUG LABEL 1 21695-062 CAPSULE 60 mg ORAL NDA 34 sections